NRG Therapeutics presents preclinical data on its novel ALS therapy
The company unveiled mechanism-of-action insights at a conference while highlighting upcoming human trials scheduled for later this year and phase two studies in 2027.
See the latest news and media coverage for NRG Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage neuroscience company developing mitochondrial-targeted therapies for neurodegenerative diseases
nrgtherapeutics.comLast updated
In short: NRG Therapeutics advanced its lead candidate NRG5051 into first-in-human clinical trials for ALS and Parkinson's after raising £50m.
The company unveiled mechanism-of-action insights at a conference while highlighting upcoming human trials scheduled for later this year and phase two studies in 2027.
He will lead clinical development, including the Phase 1 trial of NRG5051 and a planned Phase 2 ALS study.
The trial of NRG5051 aims to restore energy in nerve cells and slow disease progression.
They thank Stevenage Bioscience Catalyst for a video sharing their story. The company focuses on treatments for ALS, MND, and Parkinson's.
Poster presentation at the ALS Association's ALS Nexus conference, August 23-26Disclosed that NRG5051 acts by inhibiting the mPTP through a novel...
Transmission electron microscope image of a thin section cut through an area of mammalian lung tissue. The high magnification image shows two mitochondria. NRG Therapeutics...
A £16 million Series A financing - led by Omega Funds - has been announced by the innovative neuroscience company NRG Therapeutics Ltd., for the...
STEVENAGE, United Kingdom, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NRG Therapeutics Ltd. ("NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial...
Track NRG Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to NRG Therapeutics and other trending companies.